BIOMAT Database Logo BIOMAT Database Logo

Prolongation of xenograft survival by soluble complement receptor type 1 and antithrombin-III combination therapy. 1996

I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Second Department of Surgery, Kyoto Prefectural University of Medicine, Japan.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011951 Receptors, Complement Molecules on the surface of some B-lymphocytes and macrophages, that recognize and combine with the C3b, C3d, C1q, and C4b components of complement. Complement Receptors,Complement Receptor,Complement Receptor Type 1,Receptor, Complement
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000990 Antithrombin III A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily. Heparin Cofactor I,Antithrombin III-Alpha,Atenativ,Heparin Co-Factor I,Kybernin,Serpin C1,Thrombate III,Antithrombin III Alpha,Antithrombin IIIAlpha,Cofactor I, Heparin,Heparin Co Factor I

Related Publications

I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Prolongation of guinea pig cardiac xenograft survival in rats by soluble human complement receptor type 1.
April 1992, Transplantation proceedings,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Prolongation of cardiac xenograft survival by depletion of complement.
April 1993, Transplantation,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Prolongation of discordant renal xenograft survival by depletion of complement. Comparative effects of systemically administered cobra venom factor and soluble complement receptor type 1 in a guinea-pig to rat model.
January 1994, Transplant international : official journal of the European Society for Organ Transplantation,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
The effect of soluble complement receptor type 1 on hyperacute xenograft rejection.
November 1991, Transplantation,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection.
April 1992, Transplantation proceedings,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Effect of repetitive high-dose treatment with soluble complement receptor type 1 and cobra venom factor on discordant xenograft survival.
August 1996, Transplantation,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin.
January 1999, Transplantation proceedings,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Prolongation of islet xenograft survival by cryopreservation.
September 1987, Diabetes,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Prominent prolongation of islet xenograft survival in combination therapy with FK 506 and 15-deoxyspergualin.
February 1991, Transplantation proceedings,
I Fujiwara, and H Nakajima, and K Arakawa, and K Akioka, and K Takeshita, and T Oka
Activation of complement by DMSO and ethanol and its inhibition by soluble complement receptor type 1.
May 1995, Biochemical Society transactions,
Copied contents to your clipboard!